Trexquant Investment LP Purchases 193,620 Shares of MiMedx Group, Inc $MDXG

Key Points

• Trexquant Investment LP increased its stake in MiMedx Group by 87.5%, now holding over 414,882 shares valued at approximately $3.15 million.
• MiMedx Group's stock received positive ratings from analysts, with Cantor Fitzgerald raising its price target from $11.00 to $12.00 and a consensus rating of "Buy."
• The company's recent earnings exceeded expectations, reporting $0.10 EPS against an estimate of $0.06, alongside revenue of $98.61 million, surpassing the projected $90.79 million.

Trexquant Investment LP grew its holdings in MiMedx Group, Inc (NASDAQ:MDXG - Free Report) by 87.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 414,882 shares of the company's stock after purchasing an additional 193,620 shares during the period. Trexquant Investment LP owned approximately 0.28% of MiMedx Group worth $3,153,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in shares of MiMedx Group by 15.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock valued at $17,338,000 after purchasing an additional 238,075 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of MiMedx Group in the fourth quarter worth about $450,000. Raymond James Financial Inc. purchased a new stake in shares of MiMedx Group in the fourth quarter worth about $887,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of MiMedx Group by 18.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,713 shares of the company's stock worth $302,000 after buying an additional 6,090 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after buying an additional 2,837 shares in the last quarter. Institutional investors own 79.15% of the company's stock.

MiMedx Group Price Performance

NASDAQ MDXG traded up $0.01 on Monday, reaching $7.15. 27,238 shares of the company's stock traded hands, compared to its average volume of 669,529. MiMedx Group, Inc has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. The stock has a 50-day simple moving average of $6.90 and a 200 day simple moving average of $6.99. The stock has a market cap of $1.06 billion, a PE ratio of 34.00 and a beta of 1.74.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.04. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The business had revenue of $98.61 million for the quarter, compared to analysts' expectations of $90.79 million. As a group, research analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on MDXG shares. Cantor Fitzgerald increased their price target on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Wall Street Zen raised shares of MiMedx Group from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, MiMedx Group currently has an average rating of "Buy" and a consensus price target of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.